Navigating Flares and Daily Symptoms
At a Glance
An RRMS relapse causes new or clearly worsening neurological symptoms lasting at least 24 hours without fever or infection, while a pseudorelapse temporarily revives old symptoms after heat, illness, stress, or poor sleep; prompt assessment guides treatment.
Living with Relapsing-Remitting Multiple Sclerosis (RRMS) involves managing two different types of challenges: the sudden “storms” of relapses and the “background noise” of daily symptoms. Understanding how to distinguish between these and knowing the tools available for each can help you feel more in control of your health [1][2].
Is it a True Relapse?
A relapse (also called a flare, attack, or exacerbation) is a clear sign of new inflammatory activity in your central nervous system. To be considered a “true” relapse, the symptoms must meet specific criteria [1]:
- New or Worsening: You experience new neurological symptoms (like vision loss or limb weakness) or a significant worsening of old ones.
- Duration: The symptoms must last continuously for at least 24 hours.
- No Infection/Fever: The symptoms must occur without an underlying fever or active infection.
- Stability: They must begin at least 30 days after the onset of your previous relapse.
Because infections, strokes, or severe migraines can mimic MS flares, contact your MS team promptly for evaluation rather than trying to classify a relapse alone.
The “Pseudorelapse”
It is common for old MS symptoms to temporarily “re-awaken” or feel worse during times of physical stress. This is known as a pseudorelapse. It is not caused by new damage to your nerves, but rather by the body’s temporary inability to conduct signals efficiently through old areas of scarring [3]. Common triggers include:
- Fever or infections (even a minor cold or UTI) [1].
- Heat exposure (Uhthoff’s phenomenon).
- High stress, overexertion, or poor sleep.
Once the trigger is addressed—for example, once a fever breaks or you cool down—pseudorelapse symptoms typically fade away [1]. Do not try to self-treat a pseudorelapse with leftover steroids.
Treating Acute Relapses
If a relapse is “functionally significant”—meaning it affects your vision, balance, or ability to work—your doctor may recommend treatment to speed up recovery [3].
- Corticosteroids: The standard treatment is high-dose methylprednisolone. This can be given through an IV or as equivalent high-dose oral pills (standard low-dose oral steroids are not equivalent); studies show that the high-dose oral and IV versions are comparable for most people [4][5]. While steroids help you recover faster from the immediate attack, they do not change your long-term underlying disability outcome [3].
- Plasma Exchange (Plasmapheresis): If a severe relapse does not respond to steroids, your doctor may suggest plasma exchange. This specialized procedure filters your blood to remove inflammatory proteins. It carries procedure-related risks and is an escalation option for severe, refractory attacks [6][7].
Managing Daily Symptoms
Many people with RRMS experience lingering symptoms even when they are in “remission.” These are managed through a combination of lifestyle changes, therapy, and medication.
Fatigue
MS fatigue is more than just feeling tired; it is an overwhelming sense of exhaustion that isn’t always fixed by sleep. Management should be individualized:
- Physical Strategy: While some people benefit from aerobic or resistance training, others require strict energy conservation. Working with an MS-trained physical or occupational therapist ensures your routine is safe and accounts for heat sensitivity and balance [8].
- Behavioral Strategy: Cognitive Behavioral Therapy (CBT) and mindfulness-based interventions can help you manage the mental toll of fatigue, address sleep problems, and improve daily functioning [9].
Spasticity
Spasticity is a feeling of stiffness or involuntary muscle spasms.
- Management: Stretching and physical therapy are the first lines of defense. Medications like baclofen or tizanidine are commonly used to relax the muscles [10]. For severe cases that don’t respond to standard pills, specialized options (like an add-on THC:CBD spray, where legally available) may be considered, though these come with cautions regarding sedation and driving [10].
Bladder and Bowel Health
MS can disrupt the signals between your brain and your bladder or bowels.
- Urological Assessment: If you experience urgency, frequency, or “accidents,” it is important to see a urologist. They may check your post-void residual (PVR)—a simple ultrasound to see if your bladder is emptying completely [11][12].
- Interventions: Management may include pelvic-floor muscle training, medications like mirabegron, or clean intermittent catheterization (CIC) if the bladder is not emptying properly [13][14][15].
- Bowel Health: For constipation or fecal incontinence, a consistent bowel regimen and lifestyle adjustments are the starting points [16].
Remember, you do not have to “just live with” these symptoms. Each one has a specific management strategy designed to help you maintain your independence and quality of life.
Common questions in this guide
How can I tell whether my MS symptoms are a true relapse?
What can trigger an MS pseudorelapse?
Can high-dose oral steroids work as well as IV steroids for an MS relapse?
When might plasma exchange be used for an MS flare?
What can help manage fatigue caused by RRMS?
How are bladder problems evaluated and treated in RRMS?
Related questions
Get notified when new evidence is published on relapsing-remitting multiple sclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Repository corticotropin injection in multiple sclerosis: an update.
Kutz CF, Dix AL
Neurodegenerative disease management 2018; (8(4)):217-225 doi:10.2217/nmt-2018-0008.
PMID: 29869572 - 2
Management of Multiple Sclerosis Relapses.
Repovic P
Continuum (Minneapolis, Minn.) 2019; (25(3)):655-669 doi:10.1212/CON.0000000000000739.
PMID: 31162310 - 3
Therapeutic management of severe relapses in multiple sclerosis.
Bevan C, Gelfand JM
Current treatment options in neurology 2015; (17(4)):345 doi:10.1007/s11940-015-0345-6.
PMID: 25794777 - 4
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Le Page E, Veillard D, Laplaud DA, et al.
Lancet (London, England) 2015; (386(9997)):974-81.
PMID: 26135706 - 5
Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
Liu S, Liu X, Chen S, et al.
PloS one 2017; (12(11)):e0188644 doi:10.1371/journal.pone.0188644.
PMID: 29176905 - 6
Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis.
Lipphardt M, Wallbach M, Koziolek MJ
Journal of clinical medicine 2020; (9(5)) doi:10.3390/jcm9051597.
PMID: 32466101 - 7
Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study.
Blechinger S, Ehler J, Bsteh G, et al.
Therapeutic advances in neurological disorders 2021; (14()):1756286420975642 doi:10.1177/1756286420975642.
PMID: 33552236 - 8
High-intensity resistance training in multiple sclerosis - An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition.
Kierkegaard M, Lundberg IE, Olsson T, et al.
Journal of the neurological sciences 2016; (362()):251-7.
PMID: 26944158 - 9
Online psychological interventions to improve symptoms in multiple sclerosis: A systematic review: Online psychological interventions in Multiple Sclerosis.
Montañés-Masias B, Bort-Roig J, Pascual JC, et al.
Acta neurologica Scandinavica 2022; (146(5)):448-464 doi:10.1111/ane.13709.
PMID: 36121184 - 10
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Arroyo González R
Expert review of neurotherapeutics 2018; (18(10)):785-791 doi:10.1080/14737175.2018.1510772.
PMID: 30235965 - 11
Neurourological assessment in people with multiple sclerosis (MS): a new evaluated algorithm.
Domurath B, Kurze I, Kirschner-Hermanns R, et al.
Multiple sclerosis and related disorders 2020; (44()):102248 doi:10.1016/j.msard.2020.102248.
PMID: 32562907 - 12
Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.
Medina-Polo J, Adot JM, Allué M, et al.
Neurourology and urodynamics 2020; (39(2)):762-770 doi:10.1002/nau.24276.
PMID: 31943361 - 13
Pelvic floor muscle training in multiple sclerosis patients with lower urinary tract dysfunction: A systematic review and meta-analysis.
Kajbafvala M, Ashnagar Z, Lucio A, et al.
Multiple sclerosis and related disorders 2022; (59()):103559 doi:10.1016/j.msard.2022.103559.
PMID: 35144089 - 14
Nocturia in Patients With Multiple Sclerosis.
Peyronnet B, Krupp LB, Reynolds WS, et al.
Reviews in urology 2019; (21(2-3)):63-73.
PMID: 31768133 - 15
Lower urinary tract dysfunction in patients with multiple sclerosis.
Panicker JN, Fowler CJ
Handbook of clinical neurology 2015; (130()):371-81.
PMID: 26003255 - 16
Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies.
Preziosi G, Gordon-Dixon A, Emmanuel A
Degenerative neurological and neuromuscular disease 2018; (8()):79-90 doi:10.2147/DNND.S138835.
PMID: 30584387
This page is for informational purposes only and does not constitute medical advice. New or worsening symptoms should be discussed promptly with your MS team, who can determine whether you need evaluation or treatment.